Slimming Jab Discontinuation Associated with Rapid Weight Regain

New research recently published in The British Medical Journal, a systematic review and meta-analysis that included 37 trials and 9,000+ participants, indicates that individuals who discontinue GLP-1 receptor agonist therapy—including commonly prescribed medications such as Ozempic, Mounjaro, and Wegovy—experience weight regain at rates up to four times faster than those who achieve weight loss through traditional diet-and exercise-based programmes alone.

These recent findings suggest that short-term use of GLP-1 injections do not provide long-term benefits as a weight loss strategy. Moreover, it indicates that these medications are most appropriately used to manage obesity and related metabolic conditions in individuals with significant clinical risk.

Rapid weight gain after discontinuation could be due to the fact that, when used alone, GLP-1 therapies do not address the underlying drivers of weight gain in otherwise healthy individuals because they do not correct metabolic dysfunction, such as disrupted appetite regulation, insulin resistance, and impaired energy balance.

Personalised nutritional therapy can support individuals coming off GLP-1 therapy, as well as those seeking a natural approach to sustained weight management over slimming injections. This includes personalised programmes, like Metabolic Balance®, which helps to reduce inflammation, support appetite regulation and insulin sensitivity, and promote sustainable weight management using whole foods.

Learn more how nutritional therapy can support you at: www.karius.ch

For further details on the most recent research, visit:

https://www.bmj.com/content/392/bmj-2025-085304

KATHLEEN KARIUS

Functional Nutrition and Wellbeing